Perspective Therapeutics (NYSE:CATX) Given “Outperform” Rating at Wedbush

Wedbush reiterated their outperform rating on shares of Perspective Therapeutics (NYSE:CATX) in a report issued on Wednesday morning,RTT News reports. Wedbush currently has a $11.00 target price on the stock.

Other equities analysts have also recently issued reports about the company. HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of Perspective Therapeutics in a report on Wednesday, March 19th. Royal Bank of Canada reissued an “outperform” rating and issued a $16.00 target price on shares of Perspective Therapeutics in a research report on Tuesday, January 14th. Lifesci Capital upgraded shares of Perspective Therapeutics to a “strong-buy” rating in a research note on Thursday, March 6th. Brookline Capital Management raised shares of Perspective Therapeutics to a “strong-buy” rating in a report on Monday, March 10th. Finally, Cantor Fitzgerald raised shares of Perspective Therapeutics to a “strong-buy” rating in a report on Tuesday, March 4th. One research analyst has rated the stock with a hold rating, eight have assigned a buy rating and three have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $14.56.

Perspective Therapeutics Price Performance

CATX opened at $2.27 on Wednesday. Perspective Therapeutics has a twelve month low of $2.24 and a twelve month high of $19.05. The firm has a 50 day moving average price of $2.98 and a 200-day moving average price of $6.54.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of CATX. Y Intercept Hong Kong Ltd bought a new stake in Perspective Therapeutics during the fourth quarter valued at about $33,000. Intech Investment Management LLC purchased a new stake in shares of Perspective Therapeutics during the third quarter worth about $137,000. Aigen Investment Management LP purchased a new stake in shares of Perspective Therapeutics during the fourth quarter worth about $34,000. National Bank of Canada FI raised its stake in Perspective Therapeutics by 549,900.0% during the 4th quarter. National Bank of Canada FI now owns 11,000 shares of the company’s stock valued at $35,000 after purchasing an additional 10,998 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in Perspective Therapeutics in the 3rd quarter worth approximately $152,000. Hedge funds and other institutional investors own 54.66% of the company’s stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.